MIAMI (PRWEB) October 01, 2013
The Global Stem Cells Group, Inc. has announced a worldwide alliance with Fort Myers, Florida-based EmCyte Corporation to promote in- office regenerative medicine procedures for physicians and practitioners.
EmCyte, a leading provider of biotechnology solutions in the United States, develops biological products for platelet rich plasma and bone marrow concentrate grafting procedures. The company also manufactures proprietary devices designed for harvesting the patient’s own plasma or bone marrow to use for the patient’s treatment.
EmCyte provides clinical support and trains physicians in using biologics for sports and general rehabilitative procedures. EmCyte is now seeking to expand its operations trough the Global Stem Cells Group Network.
The Global Stem Cells Group’s collaboration with EmCyte is a logical one, as both companies are committed to research and development of products and procedures that will bring stem cell treatments to patients right in the physician’s office.
Through its six separate stem cell companies, Global Stem Cell Group is dedicated to finding opportunities like the EmCyte alliance that help expand the reach of stem cell therapy to all patients who can benefit from it.
For more information on stem cell research, products and therapies, visit the Global Stem Cell Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.
About the Global Stem Cell Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
To learn more about Global Stem Cells Group, Inc., and for investor information, visit the Global Stem Cell Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.
Read the full story at http://www.prweb.com/releases/GlobalStemCellsGroup/Emcyte/prweb11181800.htm.
Copyright©2012 Vocus, Inc.
All rights reserved